John Reilly

John brings sixteen years of experience in the biotechnology industry and has led the company since its inception in 2017. Prior to co-founding Apic, Mr. Reilly served as head of corporate and business development at Tetragenetics where he led strategic partnering efforts with Amgen, Pfizer, and MedImmune and transformed the company from a drug-discovery platform to a product focused company.

Prior to Tetragenetics, he co-founded and served as CEO of Gendyne Therapeutics. John is active in the Massachusetts biotechnology ecosystem having served for several years as a co-chair of the MassBio Business Development and Finance Committee and MassConnect mentor. He holds a B.A. from Hamilton College and M.S. and M.B.A. degrees from Cornell University.